Astera Legal advised ARCHIMED and ZytoMax GmbH on the refinancing and recapitalisation of the ZYTOMICS Group

Astera Legal advised ARCHIMED SAS and ZytoMax GmbH on the refinancing and recapitalisation of the ZYTOMICS Group by funds managed and advised by Ares Management Limited.

Founded in 2021, ZYTOMICS is a combination of European cancer diagnostics companies. All original founders of these companies shared the same vision: enabling clinical pathologists to provide a precise and timely cancer diagnosis. Unified under ZYTOMICS, the vision of the founders is proudly carried on. ZYTOMICS has established a leading presence in major European markets and is consistently growing the business as well as beyond European borders. Operations are located across sites in Northern Germany, Austria, Switzerland, and Southern France. The international distribution network covers more than 90 countries.

ARCHIMED is a global investment company focussed on the healthcare sector and currently manages funds in the amount of eight billion euros. They collaborate with scientists, healthcare professionals, entrepreneurs, and investors to positively influence companies within these industries. The focus is on assisting these companies with international expansion, increasing capacity, broadening their product ranges, and facilitating acquisitions.

Ares Management is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across credit, real estate, private equity, and infrastructure asset classes.

The Astera Legal team led by Partner Dr Bernd Egbers included Senior Associate Philipp Hogrefe, Associates Benedikt Ruck and Daniel Kriesmair.

Latham & Watkins LLP acted as legal advisor to Ares Management led by Alexandra Hagelüken and included Sybille Münch, Anna-Maria Kuckerz and Johanna Wörle.

Astera Legal is a high-end boutique law firm advising on all types of national and international complex financing structures.